Physician profile
Elaina Engler
NPI 1538902929
$1,454.23
in general payments reported to CMS, 2019-2025
7 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $136 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,454.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $436.54 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $399.31 | 2025 | Tremfya |
| Abbvie INC. | $362.56 | 2025 | |
| Kerecis Limited | $136.08 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Novo Nordisk INC | $85.10 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $17.41 | 2025 | Voquezna |
| Mirum Pharmaceuticals, INC. | $17.23 | 2025 | Chenodal, Cholbam, Livmarli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaina Engler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.